(CercleFinance.com) – Valneva announces that the European Medicines Agency (EMA) has deemed admissible its marketing authorization application (MA) for its single-dose vaccine candidate against chikungunya VLA1553.
“The chikungunya virus, or CHIKV, has already spread to more than 110 countries and the risk of chikungunya spreading in Europe is relatively high due to the possibility of infected travelers,” said Juan Carlos Jaramillo, chief medical officer of Valneva.
VLA1553 was approved by the US FDA in early November under the brand name Ixchiq. In mid-November, Valneva also announced positive results from a pivotal phase III study in adolescents investigating the immunogenicity of the product.